The Trump administration could bring down drug prices. But it would take guts
From the article:
“If Price and [President] Trump are interested in lower-priced drugs, they have access to a tool that enables them to do that,” explained Rachel Sachs, an associate professor at the Washington University School of Law who participated in the informal panel advising Louisiana. “This has been invoked repeatedly by the federal government regarding other technologies.”
Of course, this is no slam dunk.
The law allows HHS to get around the patent, but the Food and Drug Administration also offers market exclusivity periods that may run beyond a patent. The time frame varies for each drug, although as Sachs pointed out, the first exclusivity for Sovaldi runs out next year.
Read more here!bioethics fda health care finance health care reform health law policy pharmaceuticals rachel sachs regulation